Paroxysmal supraventricular tachycardia epidemiology and demographics: Difference between revisions
Homa Najafi (talk | contribs) (Created page with "__NOTOC__ {{Paroxysmal supraventricular tachycardia}} {{CMG}}; {{AE}}{{Noha}} Category:Cardiology Category:Cardiovascular diseases Category:Arrythmia Category:E...") |
Homa Najafi (talk | contribs) No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 2: | Line 2: | ||
{{Paroxysmal supraventricular tachycardia}} | {{Paroxysmal supraventricular tachycardia}} | ||
{{CMG}}; {{AE}}{{Noha}} | {{CMG}}; {{AE}}{{Noha}} | ||
==Overview== | |||
==Epidemiology and Demographics== | |||
===Incidence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
===Prevalence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | |||
===Case-fatality rate/Mortality rate=== | |||
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%. | |||
*The case-fatality rate/mortality rate of [disease name] is approximately [number range]. | |||
===Age=== | |||
*Patients of all age groups may develop [disease name]. | |||
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years. | |||
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age. | |||
*[Chronic disease name] is usually first diagnosed among [age group]. | |||
*[Acute disease name] commonly affects [age group]. | |||
===Race=== | |||
*There is no racial predilection to [disease name]. | |||
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | |||
===Gender=== | |||
*[Disease name] affects men and women equally. | |||
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | |||
===Region=== | |||
*The majority of [disease name] cases are reported in [geographical region]. | |||
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2]. | |||
===Developed Countries=== | |||
===Developing Countries=== | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Cardiovascular diseases]] | [[Category:Cardiovascular diseases]] | ||
[[Category: | [[Category:Arrhythmia]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Disease]] | [[Category:Disease]] |
Latest revision as of 03:08, 24 May 2020
Paroxysmal supraventricular tachycardia Microchapters |
Differentiating Paroxysmal supraventricular tachycardia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Paroxysmal supraventricular tachycardia epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Paroxysmal supraventricular tachycardia epidemiology and demographics |
FDA on Paroxysmal supraventricular tachycardia epidemiology and demographics |
CDC on Paroxysmal supraventricular tachycardia epidemiology and demographics |
Paroxysmal supraventricular tachycardia epidemiology and demographics in the news |
Blogs on Paroxysmal supraventricular tachycardia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Noha Elzeiny, M.B.B.Ch, M.Sc.[2]
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].